While drug-makers have agreed to an $80 billion in fees and hospitals agreed to a $155 billion cut in Medicare reimbursements over the next decade as part of health reform, device-makers did not cooperate with the finance committee and the committee chose the payment level without negotiating with the industry.
Now the device industry is engaged in an extensive campaign to have the fee removed from the legislation.
Read USA Today’s feature on the orthopedic device industry.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
